Results of patients with t(8;21) or inv(16) treated with or without HAM
| . | t(8;21) . | inv(16) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HAM . | No HAM . | P . | HAM . | No HAM . | P . | |||||
| n . | % . | n . | % . | n . | % . | n . | % . | |||
| No. of patients | 78 | 53 | 43 | 46 | ||||||
| Nonresponders | 0 | 0 | 3 | 6 | .08 | 0 | 0 | 0 | 0 | |
| CR achieved | 78 | 100 | 50 | 94 | .24 | 43 | 98 | 46 | 100 | .30 |
| Death in CCR | 2 | 3 | 1 | 2 | .55 | 2 | 5 | 0 | 0 | .14 |
| Relapse (cumulative incidence) | 14 ± 4 | 34 ± 7 | .006 | 15 ± 6 | 23 ± 8 | .44 | ||||
| Secondary malignancies | 1 | 1 | 0 | 0 | 2 | 5 | 1 | 2 | ||
| P (survival 5 y) | 92 ± 3 | 80 ± 6 | .047 | 93 ± 4 | 94 ± 4 | .69 | ||||
| P (EFS 5 y) | 84 ± 4 | 59 ± 7 | .001 | 75 ± 7 | 71 ± 9 | .95 | ||||
| . | t(8;21) . | inv(16) . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HAM . | No HAM . | P . | HAM . | No HAM . | P . | |||||
| n . | % . | n . | % . | n . | % . | n . | % . | |||
| No. of patients | 78 | 53 | 43 | 46 | ||||||
| Nonresponders | 0 | 0 | 3 | 6 | .08 | 0 | 0 | 0 | 0 | |
| CR achieved | 78 | 100 | 50 | 94 | .24 | 43 | 98 | 46 | 100 | .30 |
| Death in CCR | 2 | 3 | 1 | 2 | .55 | 2 | 5 | 0 | 0 | .14 |
| Relapse (cumulative incidence) | 14 ± 4 | 34 ± 7 | .006 | 15 ± 6 | 23 ± 8 | .44 | ||||
| Secondary malignancies | 1 | 1 | 0 | 0 | 2 | 5 | 1 | 2 | ||
| P (survival 5 y) | 92 ± 3 | 80 ± 6 | .047 | 93 ± 4 | 94 ± 4 | .69 | ||||
| P (EFS 5 y) | 84 ± 4 | 59 ± 7 | .001 | 75 ± 7 | 71 ± 9 | .95 | ||||